|
MRPL32 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.64723790163634E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.82385226313409E-12 |
| Normal-vs-Stage2 |
1.812140E-02 |
| Normal-vs-Stage3 |
1.88737914186277E-15 |
| Normal-vs-Stage4 |
1.64834812466097E-12 |
| Stage1-vs-Stage2 |
3.191900E-02 |
| Stage1-vs-Stage3 |
2.679200E-03 |
| Stage1-vs-Stage4 |
2.860200E-03 |
| Stage2-vs-Stage3 |
4.177500E-04 |
| Stage2-vs-Stage4 |
1.971740E-04 |
| Stage3-vs-Stage4 |
5.107800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.63991042967382E-12 |
| Normal-vs-AfricanAmerican |
1.40719658148214E-11 |
| Normal-vs-Asian |
5.22470000596797E-09 |
| Caucasian-vs-AfricanAmerican |
3.227700E-02 |
| Caucasian-vs-Asian |
3.258400E-01 |
| AfricanAmerican-vs-Asian |
4.523600E-03 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.86173298999393E-12 |
| Normal-vs-Female |
1.69553260320754E-12 |
| Male-vs-Female |
5.968400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.00339736519572E-11 |
| Normal-vs-Age(41-60Yrs) |
1.18993703779324E-12 |
| Normal-vs-Age(61-80Yrs) |
2.90223400867262E-12 |
| Normal-vs-Age(81-100Yrs) |
4.31320000000568E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.578800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.826430E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.894200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.436600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.890800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.254200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.200250E-02 |
| Classical-VS-Follicular |
5.766900E-04 |
| Classical-VS-Other |
7.318200E-01 |
| Classical-VS-Normal |
5.98410210272959E-14 |
| Tall-VS-Follicular |
3.7244999999686E-06 |
| Tall-VS-Other |
3.002400E-01 |
| Tall-VS-Normal |
1.72439840184779E-12 |
| Follicular-VS-Other |
6.225000E-01 |
| Follicular-VS-Normal |
8.3953000000081E-05 |
| Other-VS-Normal |
1.806170E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.93749469193472E-11 |
| Normal-vs-N1 |
1.03689945518681E-10 |
| N0-vs-N1 |
2.007800E-02 |
|
|
